PU.1-activated genomic regions define low-risk MDS subsets characterized by immune dysregulation and disease progression

作者：V. Vallelonga, Francesco Gandolfi, Matteo Zampini, E. Riva, G. Maggioni, Denise Ventura, Elena Saba, A. Termanini, S. Polletti, Elena Prosperini, L. Crisafulli, Alessia Campagna, Ivan Ferrari, Nicole Pinocchio, G. Todisco, S. Pedretti, M. Calvi, C. Di Vito, Domenico Mavilio, N. Mitro, F. Ficara, M. D. Della Porta, S. M. L. Ghisletti · 发表于：Blood · 年份：2026 · DOI：10.1182/blood.2025030760 · 被引用次数：3 · 研究领域：Medicine

Key Points • Genomic and transcriptional profiling reveals early molecular changes in low-risk MDS associated with progression to high-risk MDS and sAML.• PU.1 binding to immune-linked regions is associated with SRSF2 mutation, increased risk of disease progression, and reduced survival.